

### Investment Objective

The Strategy invests in Sharia compliant equities across the major markets, with the objective of generating returns in excess of the benchmark, over a 3-5 year period.

### Investment Manager

Rasameel Investment Company KSCC

### Time Horizon

Longterm

### Inception Date

01/11/2016

### Base Currency

USD

### Benchmark Index

MSCI World Islamic index

### Top Holdings


Company	Weight
MRK US	3.1%
YCA LN	2.7%
AZN LN	2.4%
NOVN SW	2.4%
META US	2.4%

Characteristics	Strategy
TTM P/E	14
P/B	2.24
P/CF	9.17
Dividend Yield	3.04%
Debt/Equity	0.45

Returns	Strategy (Gross)	Benchmark (Net)
MTD	-4.1%	-2.0%
YTD	1.0%	3.3%
ITD	55.4%	62.6%

Risk Statistics - 1Yr	Strategy	Benchmark
Std. Dev	16.9%	19.0%
Downside Risk	12.2%	13.4%
MC VAR	23.5%	29.5%
BETA (ex-post)	0.82	1.00
Correlation	0.92	1.00
Sharpe Ratio	-0.50	-0.2
IR	-0.68	NA

### Performance




Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	Benchmark
2023 (%)	5.3	-4.1											1.0	3.3
2022 (%)	-1.6	0.5	1.5	-5.9	0.8	-6.1	2.2	-0.8	-8.1	4.3	6.6	-1.7	-9.1	-11.7
2021 (%)	1.0	4.1	0.8	0.7	2.2	-0.8	-3.2	-2.7	-4.1	5.4	-2.3	2.6	3.6	21.9
2020 (%)	-2.8	-5.5	-6.8	8.1	6.0	3.8	6.1	2.1	-3.8	0.1	7.1	6.2	21.1	7.8
2019 (%)	9.6	3.6	-0.6	7.6	-10.3	7.1	0.6	-1.1	-0.5	2.7	2.6	4.4	26.9	22.1
2018 (%)	6.6	-3.6	-3.1	1.5	0.9	-0.9	0.8	0.3	-2.7	-9.5	-3.1	-6.4	-18.1	-9.9
2017 (%)	0.9	3.5	3.6	0.9	0.8	-0.9	1.8	1.8	4.5	2.1	2.5	1.2	23.9	19.1
2016 (%)											0.7	3.1	3.8	3.6


### 30 Day Top Contributors & Detractors

Contributors	Return	Cont.	Detractors	Return	Cont.
META US	17.4%	0.3%	9618 HK	-25.1%	-0.6%
NVDA US	18.8%	0.2%	ARNGF US	-36.4%	-0.4%
GFS US	10.2%	0.2%	AEM US	-17.8%	-0.3%
SHEL LN	5.7%	0.1%	DVN US	-14.7%	-0.3%
CRWD US	14.0%	0.1%	AKAM US	-18.4%	-0.3%

### Geographic Breakdown



### Sector Breakdown



\* The performance shown above is gross of all fees and unaudited. Past performance is not indicative of future returns.

### Disclaimer:

This document is prepared for promotional purposes. The performance stated above is for a composite of client accounts and is gross of all fees and commissions. Actual client performance may vary from the composite. Rasameel Investment Company hereby undertakes that it does not disguise, diminish or obscure important items from the investment subject of promotion.

### Warning:

The past performance of any investment or a product is not a reliable indicator of future results and it cannot be relied upon for investment decision making.

### Commentary

Rasameel Global Strategy endured a difficult month which saw the strategy decline 4%, underperforming the MSCI World Islamic Index, which was down 2% in February. The benchmark outperformed mainly due its positioning in Tesla, which is the index's 2nd largest holding, up 90% in the first 2 months of the year. We are incrementally cautious on the rally YTD, as we have seen such bull traps in prior periods (2008, 2001, 1973-4). Q4 earnings have ended, with a blended YoY earnings decline of 4.6% on the S&P 500, which continues to trade slightly above the 10-year average of 17.5x. To add to this, analysts have further lowered CY23 estimates by another 3.4% since the start of the year. Therefore, we think we are currently well positioned, with plenty of dry powder to add back if we see a more drastic sell-off.

During the month, **Meta Platforms (META US)** returned 17.4%, continuing its strong performance from the prior month (up 40% YTD). The company beat Q4 revenue estimates, but missed on EPS, albeit accounting for restructuring charges which amounted to \$4.2 billion. For the current fiscal year, Meta aims to reign in opex and capex, with the aim of focusing on efficiency and profitability. Elsewhere, **Nvidia (NVDA US)** was up 18.8% in February (up 62% YTD) as management guided to sequential growth in data center and gaming, which suggests sales channels normalizing. In addition, the investment rationale for NVDA is strengthening as it looks to capitalize on the generative AI opportunity brought forth by the likes of ChatGPT. **Globalfoundries (GFS US)** returned 10.2% during the month on the back of revenue and earnings for Q4 which came ahead of consensus. The company also cited ASP growth of 20% YoY, which reflects positively on execution during a period witnessing weak consumer end-market demand. We expect upcoming catalysts in the form of US Chips Act funding allocation and EU semiconductor funding measures over the course of the year, as well as GFS's Singapore Fab ramping up revenue in 2H23.

With regards to detractors during the month, **JD.com (9618 HK)** declined 25%, as Chinese e-commerce names struggle with weak online sales to start the year, and a drop in global demand for Chinese exports. With that said, however, JD.com's most recent quarter saw revenue rise 11%, and a rebound may be underway as China emerges from the slowdown induced by zero-Covid policy. Next up, **Argonaut Gold (ARNGF CA)** was down 36.4%, as gold spot prices declined 5.3% in February, and the company saw inflationary pressures and inventory write-downs increase AISC. However, the company has been proactive in selling off non-core assets and revising mine plans at the 3 locations to focus on free cash flow generation. We saw January CPI reading come in at a 3-month high and above consensus, and therefore, are happy with our positioning to gold miners as a hedge to stubborn inflation. **Agnico Eagle Mines (AEM US)** endured a weak month, down 17.8% during the month, also driven by a hot US January inflation report which may have revised the Fed's rate-hike path higher. Nonetheless, the company ended the year achieving record production, growing 50% from the prior year.

We continue to be cautious on the equity market and consider it probable that we will see another leg lower. We are though, very selectively looking to add exposure to names that we believe are due a technical bounce and whose fundamentals are intact. We will add aggressively once we feel the market has sufficiently priced in the expected weaker earnings outlook.

### Disclaimer

*This document is not directed at or intended for use by any person resident or located in any jurisdiction where the distribution of such information is contrary to the laws of such jurisdiction, or such distribution is prohibited without obtaining the necessary licenses or authorizations. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the content. The information contained in this document is for promotional purposes only and should not be regarded by recipients as a substitute for the exercise of their own judgment. This document does not constitute a solicitation, an offer, or a recommendation to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. The performance stated above is of a model account. Rasameel Investment Company hereby undertakes that it does not disguise, diminish or obscure important items from the investment subject of promotion.*

### Warning:

*The past performance of any investment or a product is not a reliable indicator of future results and it cannot be relied upon for investment decision making.*

### Strategy Top Holdings

STOCK	INVESTMENT THESIS
	<b>Fundamental Investment Thesis</b>
<b>MERCK</b>	<b>Rationale</b> Merck & Co., Inc. is a top 5 holding in the strategy. Merck is a large-cap pharmaceutical company with a deep heritage in drug discovery. We are bullish on the continued growth of key asset Keytruda, the leading immune oncology agent used to treat a variety of cancers. We retain long-term conviction as we expect Keytruda to solidify its position. Merck's robust top-line growth should more than support its pipeline, including 8 new potential drugs by 2030. Merck sports a very strong credit rating, pays a solid and growing dividend yield, and is trading well below a 15 PE.
<b>YELLOW CAKE</b>	<b>Rationale</b> We like Uranium as it is the greenest and most reliable source of energy on the planet. With years of underinvestment in uranium supply, and demand starting to rise from China, India, and Japan, we expect uranium prices to rise much higher. Yellow Cake is our investment vehicle of choice, as it provides physical storage of uranium oxide and is currently trading at a discount around 25% to its Net Asset Value, essentially buying physical uranium at a discount. Yellow Cake is likely to trade at a premium as prices start to rise again.
<b>AMGEN</b>	<b>Rationale</b> As a big-cap biotech, Amgen has offered great relative performance as the company is growing revenue 70% in 3 years. This has been made possible by the offerings and the continued success the company sees in getting approvals for their drug readouts.
<b>NOVN SW</b>	<b>Rationale</b> Novartis is a multinational pharmaceutical corporation. Generating strong cashflow and continuously attempts to improve its pipeline. Valuation is attractive. With high cash flow and the selling its generic arm Sandoz, it will continue its growth through acquisitions and strong pipeline.
<b>JD.COM</b>	<b>Rationale</b> We see JD.com as an attractive "Quality China Internet Growth" play and one of the most attractive ways to get exposure to Chinese retail, where ecommerce penetration continues to grow. Expansion outside of China could increase JD's TAM further. The company is well positioned to improve its market share gains within the Chinese e-commerce sector. We expect 2H2022 business re-acceleration, 618 Shopping festival, OPM stability and continuing market share gains from peers to be key near-term catalysts. In addition, greater monetary easing by China in 2H2022, progress on audit cooperation with SEC, and ADR delisting fears subsiding could significantly improve investor sentiment for China internet sector companies and JD.com in particular.

### Strategy vs Peers

GLOBAL EQUITIES STRATEGY - YTD PERFORMANCE VS SIMILAR STRATEGIES

